Cargando…

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales:	Woerner, A, Uettwiller, F, Melki, I, Bader-Meunier, B, Mouy, R, Wouters, C, Quartier, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042445/ http://dx.doi.org/10.1186/1546-0096-11-S2-P146

Ejemplares similares

Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
por: Woerner, A, et al.
Publicado: (2015)

PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics
por: Remy Piccolo, V, et al.
Publicado: (2013)

Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre
por: Goirand, Maxime, et al.
Publicado: (2018)

The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Quartier, Pierre, et al.
Publicado: (2018)

PReS-FINAL-2109: Genetic variations in patients with juvenile idiopathic arthritis and uveitis
por: Reinards, TH, et al.
Publicado: (2013)

PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
por: Rossetto, E, et al.
Publicado: (2013)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

PReS-FINAL-2097: Evaluation of gait in children with juvenile idiopathic arthritis
por: Baydogan, SN, et al.
Publicado: (2013)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
por: Urien, Saik, et al.
Publicado: (2013)

Impact of biologics on growth in children with juvenile idiopathic arthritis
por: Uettwiller, F, et al.
Publicado: (2011)

PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis
por: Pastore, S, et al.
Publicado: (2013)

PReS-FINAL-2081: Accelerometer-assessed daily activity in juvenile idiopathic arthritis
por: Noergaard, M, et al.
Publicado: (2013)

PReS-FINAL-2018: The P53 gene polymorphisms and juvenile idiopathic arthritis
por: Kozhevnikov, A, et al.
Publicado: (2013)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

PReS-FINAL-2007: Adolescent clinic for young patients with juvenile idiopathic arthritis
por: Sørensen, SK
Publicado: (2013)

PReS-FINAL-2060: The role of stress factors in the onset of juvenile idiopathic arthritis
por: Stepanenko, N, et al.
Publicado: (2013)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

PReS-FINAL-2263: Progressive pseudorheumatoid dysplasia in differential diagnosis of juvenile idiopathic arthritis
por: Vrtíková, E, et al.
Publicado: (2013)

PReS-FINAL-2077: Lung function evaluation in a juvenile idiopathic arthritis cohort
por: Machado Vaz, I, et al.
Publicado: (2013)

PReS-FINAL-2061: Abatacept in therapy of juvenile idiopathic arthritis in real clinical practice
por: Arsenyeva, SV, et al.
Publicado: (2013)

PReS-FINAL-2066: Use of chiropractic care in danish children with juvenile idiopathic arthritis
por: Kuhn, KS, et al.
Publicado: (2013)

PReS-FINAL-2089: Temporomandibular joint involvement and quality of life in juvenile idiopathic arthritis
por: Frid, P, et al.
Publicado: (2013)

PReS-FINAL-2052: Costs of biologics in juvenile idiopathic arthritis: past, present and future
por: Prince, FH, et al.
Publicado: (2013)

PReS-FINAL-2155: Genetic variability of methotrexate transporters in patients with juvenile idiopathic arthritis
por: Zajc Avramovič, M, et al.
Publicado: (2013)

PReS-FINAL-2150: Antiocular antibodies in children with juvenile idiopathic arthritis-associated uveitis
por: Walscheid, K, et al.
Publicado: (2013)

PReS-FINAL-2170: Work disability in adult patients with juvenile idiopathic arthritis (JIA)
por: Goldenstein-Schainberg, C, et al.
Publicado: (2013)

PReS-FINAL-2138: Abatacept (orencia) in treatment of different types of juvenile idiopathic arthritis
por: Zholobova, ES, et al.
Publicado: (2013)

PReS-FINAL-2036: Proteins of the lectin pathway of the complement system in juvenile idiopathic arthritis
por: Petri, C, et al.
Publicado: (2013)

PReS-FINAL-2084: Prevalence of cervical spine involvement in children with juvenile idiopathic arthritis
por: Semolič, N, et al.
Publicado: (2013)

Systemic onset Juvenile Idiopathic Arthritis (SoJIA): a monocentric study of 114 patients
por: Melki, I, et al.
Publicado: (2011)

PReS-FINAL-2160: Intestinal microbiome in polyarticular juvenile idiopathic arthritis: a pilot study
por: Hissink Muller, PC, et al.
Publicado: (2013)

PReS-FINAL-2099: Assessing the standards of oral health in children and adolescents with juvenile idiopathic arthritis
por: Trehane, SJ, et al.
Publicado: (2013)

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis
por: Lavric, M, et al.
Publicado: (2013)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

PReS-FINAL-2104: Disease course and predictors of outcome in systemic onset juvenile idiopathic arthritis
por: Soponkanaporn, S, et al.
Publicado: (2013)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
por: Kingsbury, D, et al.
Publicado: (2013)

PReS13-SPK-1030: Juvenile dermatomyositis
por: Quartier, P
Publicado: (2013)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1f2009rrve22q17sof1oekl2cm